'Four FDA-approved drugs decrease overall mortality in humans'

Ahead of his appearance at Longevity Investors Conference, Nir Barzilai talks gerotherapeutics and choosing the right drugs for aging.

Take a unique mix of investors, scientists and entrepreneurs, a longevity-focused agenda packed with keynotes, panels and networking and put them in a glorious Swiss setting and you have the Longevity Investors Conference.

Kicking off later this month on 24th September in Gstaad, this year's LIC boasts an extended agenda with numerous networking opportunities running over 2.5 days. LIC always boasts a stellar line-up of longevity key opinion leaders, and this means that program discusses the latest trends and developments, and connects investors with state-of-the-art scientific progress.

This is the fifth edition of LIC, and one person who has been at the conference year-on-year is Director of the Einstein Institute for Aging Research at Albert Einstein College of Medicine and President of the Academy for Health and Lifespan Research Nir Barzilai. Ahead of his LIC presentation on Can we grow older without growing sicker?, we sat down with Dr Barzilai to get his take on the conference, advancements in the longevity space and the three FDA-approved drugs out-performing GLP-1 inhibitors on the gerotherapeutic scale.

Find out more about Longevity Investors Conference here: https://www.longevityinvestors.ch/lic...

------------------------------
Visit Longevity.Technology – https://bit.ly/3PwtH8Y

Follow Longevity.Technology on:
Twitter – https://bit.ly/3AMIXuq
Facebook – https://bit.ly/3z8H1v5
Instagram – https://bit.ly/3IDvVRX
LinkedIn – https://bit.ly/3yIfDmf